EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Stock Position Raised by Woodline Partners LP

Woodline Partners LP increased its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 25.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 501,724 shares of the company's stock after purchasing an additional 101,724 shares during the period. Woodline Partners LP owned 0.74% of EyePoint Pharmaceuticals worth $3,738,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. boosted its position in EyePoint Pharmaceuticals by 39.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock worth $51,000 after purchasing an additional 1,940 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in EyePoint Pharmaceuticals during the 4th quarter worth $59,000. Virtus ETF Advisers LLC purchased a new position in EyePoint Pharmaceuticals in the 4th quarter valued at about $67,000. AlphaQuest LLC boosted its position in EyePoint Pharmaceuticals by 13,246.6% in the 4th quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock valued at $73,000 after buying an additional 9,670 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in EyePoint Pharmaceuticals in the 4th quarter valued at about $76,000. 99.41% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Chardan Capital decreased their price objective on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. HC Wainwright reissued a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday. Wall Street Zen raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Finally, Mizuho decreased their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. One research analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $25.38.

EyePoint Pharmaceuticals Stock Performance

Shares of EyePoint Pharmaceuticals stock traded down $0.07 during trading on Friday, reaching $7.15. The company had a trading volume of 176,138 shares, compared to its average volume of 820,301. The company has a market cap of $491.65 million, a price-to-earnings ratio of -3.56 and a beta of 1.58. The firm's fifty day moving average is $5.84 and its 200-day moving average is $7.01. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.65). The business had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. On average, research analysts anticipate that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.